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Abstract
Vascular endothelial growth factor (VEGF) plays a central role in breast cancer development and
progression, but the mechanisms that control its expression are poorly understood. Breast cancer
tissue microarrays revealed an inverse correlation between the Forkhead transcription factor
FOXO3a and VEGF expression. Using the lapatinib-sensitive breast cancer cell lines BT474 and
SKBR3 as model systems, we tested the possibility that VEGF expression is negatively regulated
by FOXO3a. Lapatinib treatment of BT474 or SKBR3 cells resulted in nuclear translocation and
activation of FOXO3a, followed by a reduction in VEGF expression. Transient transfection and
inducible expression experiments showed that FOXO3a represses the proximal VEGF promoter
whereas another forkhead member, FOXM1, induces VEGF expression. Chromatin
immunoprecipitation and oligonucleotide pull-down assays demonstrated that both FOXO3a and
FOXM1 bind a consensus Forkhead response element (FHRE) in the VEGF promoter. Upon
lapatinib stimulation, activated FOXO3a displaces FOXM1 bound to the FHRE before recruiting
histone deacetylase 2 (HDAC2) to the promoter, leading to decreased histones H3 and H4
acetylation, and concomitant transcriptional inhibition of VEGF. These results show that
FOXO3a-dependent repression of target genes in breast cancer cells, such as VEGF, involves
competitive displacement of DNA-bound FOXM1 and active recruitment of transcriptional
repressor complexes.
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Introduction
The vascular endothelial growth factor (VEGF) family of growth factors, consisting of 6
members, VEGF-A (commonly called VEGF), VEGF-B,-C,-D,-E and the placental growth
factor (PIGF), plays a crucial role in tissue development and maintenance through regulating
the processes of vasculogenesis, angiogenesis and lymphangiogenesis (Lohela et al 2009).
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These VEGF ligands bind to 3 distinct primary receptors and 2 co-receptors to trigger
downstream intracellular signalling. Of the primary receptors, VEGFR-1 (Flt-1) and
VEGFR-2 (KDR/Flk-1) are associated predominantly with angiogenesis, and VEGFR-3
(Flt-4) to lymphangiogenesis. VEGFR-2 is expressed ubiquitously on almost all endothelial
cell types, whereas the expression of VEGFR-1 and -3 is restricted to particular vascular
supporting tissues. The neuropilin-1 and -2 receptors are co-receptors that can enhance the
binding affinity of the various VEGF-ligands to the primary receptors. Upon ligand-binding,
the VEGF receptors activate downstream signalling cascades, including the
phosphatidylinositol 3-kinase(PI3K)-Akt(PKB), the p38-MAPK, and the Raf pathways,
which in turn control the endothelial cell survival, proliferation and migration (Lentzsch et
al 2004, Pytel et al 2009). VEGF and its receptors are frequently overexpressed in human
tumours, especially in breast, non-small cell lung, colorectal, and prostate cancers (Ferrer et
al 1998, Heist et al 2008, Jain et al 2009, Schneider and Sledge 2007, Yamaguchi et al
2007). VEGF mediates angiogenesis, a process that plays a central role in the growth,
progression, and metastasis of solid tumours (Kitadai 2010, Makrilia et al 2009). In
consequence, VEGF and associated signalling pathways have been the targets for many
novel anti-cancer targeted therapeutics (Margolin 2002). For instance, bevacizumab, an anti-
VEGF antibody, has been shown to enhance response rates and prolonged progression-free
survival in metastatic breast cancer. Similarly, inhibition of the VEGF signalling by receptor
tyrosine kinase inhibitors (RTKIs), including sunitinib, decrease proliferation of numerous
cancer cells in vitro (Ikezoe et al 2006a, Ikezoe et al 2006b). Besides being a therapeutic
target, VEGF is also a rational prognostic marker in many cancers (Margolin 2002). For
example, VEGF expression in gastric cancer has been shown to be an independent negative
prognostic marker (Ferrer et al 1998, Heist et al 2008, Jain et al 2009, Schneider and Sledge
2007, Yamaguchi et al 2007).
The PI3K-Akt cell proliferation and survival signalling pathway plays a key role in
tumorigenesis of many cancers as well as in development of anti-cancer chemotherapy
resistance. The Forkhead box class O (FOXO) transcription factors are crucial downstream
effectors of the PI3K-Akt signalling pathway and are implicated in a wide variety of cellular
functions including cell proliferation, apoptosis, differentiation and resistance to oxidative
stress and DNA damage (Arden 2008, Burgering 2008, Calnan and Brunet 2008, Fu and
Tindall 2008, Gomes et al 2008, Ho et al 2008, Huang and Tindall 2007, Lam et al 2006,
Maiese et al 2008, Myatt and Lam 2007, Reedquist et al 2006). As such, deregulation of
FOXO proteins is associated with tumorigenesis and cancer progression. In addition,
emerging evidence has also demonstrated that FOXO proteins, in particular the FOXO3a,
has a central role in mediating the cytostatic and cytotoxic effects of chemotherapy
(Fernandez de Mattos et al 2004, Fernandez de Mattos et al 2008, Gomes et al 2008, Ho et al
2008, Hui et al 2008a, Hui et al 2008b, McGovern et al 2009, Myatt and Lam 2007, Sunters
et al 2003, Sunters et al 2006). The mammalian FOXO family of transcription factors
comprises of 4 members, FOXO1, FOXO3a, FOXO4 and FOXO6, and they are direct
substrates of Akt (Myatt and Lam 2007). FOXO proteins interact with a core consensus
DNA sequence GTAAA(C/T)A to modulate target gene expression. Phosphorylation of
FOXOs by Akt results in their nuclear exclusion and inactivation.
Lapatinib (GW572016) is a small molecule dual tyrosine kinase inhibitor (TKI) for HER2
and EGFR that acts through competitive inhibition of ATP-binding to the receptor tyrosine
kinase domain (Ciardiello 2005, Nelson and Dolder 2006, Wakeling 2002). Lapatinib has
been shown to cause growth delay and cell death in breast cancer cell lines and human
tumour xenografts expressing high levels of EGFR and/or HER2. Recent phase II/III clinical
studies also demonstrated that lapatinib was well tolerated and provided anti-tumour activity
in patients with breast as well as with other types of cancer when used as a monotherapy or
in combination with other anti-cancer treatments (Ciardiello 2005, Montemurro et al 2007).
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Most recent studies showed lapatinib displays antiangiogenic effect in a lung cancer model
(Diaz et al 2010) and that combination treatment of lapatinib with paclitaxel, but not
lapatinib alone, effectively inhibits angiogenesis in head and neck squamous cell carcinoma
(HNSCC) cells (Kondo et al 2010). However, whilst enhanced HER2/EGFR expression may
have been shown to function primarily through two pathways the ERK1/2 MAP kinase and
PI3K-Akt signalling cascades (Montemurro et al 2007, Yarden and Sliwkowski 2001, Zhang
et al 2007), a complete understanding of the mechanism by which HER2/EGFR promotes
tumorigenesis remains lacking. Latest work demonstrates that FOXO3a plays an essential
role in mediating the cytostatic and cytotoxic function of lapatinib as well as the EGFR
specific TKI gefitinib (Hegde et al 2007, Krol et al 2007, McGovern et al 2009).
A recent cDNA microarray study revealed that FOXO3a can potentially repress VEGF
expression in a colon carcinoma cell line (Delpuech et al 2007). In the present study, we
validated this notion in breast cancer patient samples and then went on to investigate the
molecular mechanism by which FOXO represses VEGF expression.
Results
Inverse correlation between FOXO3a and VEGF expression in breast cancer
The expression patterns of FOXO3a, FOXM1 and VEGF were examined in a panel of breast
cancer samples by immunohistochemistry. Representative patterns of staining are shown in
Figure 1A. FOXO3a immunoreactivity was predominantly cytoplasmic in most tumour
samples and correlated positively with VEGF (P = <0.001, Chi-square test) and FOXM1 (P
= 0.011, Chi-square test) staining irrespective of histological type, suggesting that the
activated nuclear FOXO3a inhibits FOXM1 and VEGF expression in vivo in most breast
cancer samples (Fig. 1B and S1-5). Notably, there was also an inverse association between
nuclear FOXO3a and VEGF expression but it was not statistically significant. Moreover,
FOXM1 expression also significantly correlated with the expression of VEGF (P=0.015,
Chi-square test), suggesting FOXM1 promotes VEGF expression in breast cancer cells (Fig.
1B and S6).
FOXO3a activation correlates with down-regulation of FOXM1 and VEGF expression
FOXM1 has recently been suggested to regulate VEGF expression (Zhang et al 2008) and to
be regulated by FOXO3a (Francis et al 2009). To determine if FOXO3a and FOXM1 also
modulates VEGF transcription, we first monitored the expression of VEGF, FOXM1, and
FOXO3a upon lapatinib treatment of responsive and resistant breast cancer cell lines.
Western blot analysis showed that lapatinib treatment of sensitive BT474 and SKBR3 cells
caused a decline in phosphorylation but an increase in nuclear FOXO3a levels, indicating
activation of this transcription factor (Fig. 2A). FOXO3a activation upon lapatinib treatment
was accompanied by a decrease in VEGF and FOXM1 levels. The result also showed that
another growth factor FGF7 was not down-regulated by lapatinib, suggesting that the
repression of VEGF expression by lapatinib and FOXO3a is specific. Notably, all factors
were down-regulated in BT474 cells after 48 h, probably reflecting global protein
degradation and cell death. In contrast, there were no appreciable changes in P-FOXO3a,
nuclear FOXO3a, FOXM1, or VEGF levels upon treatment of lapatinib-resistant MDA-
MB-231 breast cancer cells.
To confirm that lapatinib represses VEGF expression, secreted levels of VEGF were
determined by ELISA in the three cell lines (Fig. 2B). Whereas secreted VEGF levels
remained unchanged upon lapatinib treatment of MDA-MB-231 cells, the levels declined
markedly after 24 h treatment of the sensitive BT474 and SKBR3 cells. As a control, we
also measured the secreted levels of FGF7 by ELISA (Fig. S7). The results showed that the
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concentrations of the irrelevant control growth factor FGF7 did not alter significantly after
lapatinib treatment in BT474, SKBR3 and MDA-MB-231 cells, suggesting that the
repression of VEGF by FOXO3a and lapatinib is specific. We then tested if lapatinib
regulated VEGF, FOXM1 or FOXO3a expression at the transcriptional level. RT-qPCR
analysis confirmed that lapatinib inhibited VEGF and FOXM1 mRNA expression in the
sensitive SKBR3 but not the resistant MDA-MB-231 cells (Fig. 2C). Notably, FOXO3a
transcript levels were also up-regulated in SKBR3 cells. Together these results demonstrate
that lapatinib treatment of sensitive breast cancer cells induces and activates FOXO3a but
inhibits FOXM1 and VEGF expression.
FOXO3a represses VEGF and FOXM1 expression
To study the mechanism underlying the reciprocal relationship between FOXO3a activation
and VEGF and FOXM1 inhibition, we used an estrogen receptor α (ER)-negative MDA-
MB-231 cell line expressing a fusion protein containing a constitutively active FOXO3a(A3)
and ligand-binding domain of ER. In MDA-MB-231-FOXO3a(A3):ER cells, FOXO3a can
be conditionally activated by 4-hydroxytamoxifen (4-OHT). As shown in Figure 3A, 4-OHT
not only induced nuclear accumulation of activated FOXO3a but also inhibited expression
of both VEGF and FOXM1. This down-regulation of VEGF and FOXM1 upon 4-OHT
treatment was dependent upon FOXO3a activation, as no response was observed upon
treatment of control MDA-MB-231 cells. As anticipated, induction of FOXO3a activity also
decreased secreted VEGF levels, apparent at 8 h of 4-OHT stimulation, whereas this
response was absent in control MDA-MB-231 cells (Fig. 3A). Consistently, breast cancer
cells migrated at slower rates in scratch wound healing assays when cultured in supernatants
derived from FOXO3a-induced MDA-MB-231 cells (Fig. S8). Further, 4-OHT also down-
regulated VEGF and FOXM1 mRNA levels in MDA-MB-231-ER:FOXO3a(A3) cells,
relative to control cells (Fig. 3B), inferring that FOXM1 and VEGF expression is negatively
regulated by FOXO3a at a transcriptional level.
To corroborate these observations, MCF-7 breast carcinoma cells were transiently
transfected with the constitutively active FOXO3a(A3) or control empty expression vectors,
and VEGF and FOXM1 expression monitored. Western blot and RT-qPCR analyses
demonstrated that the FOXO3a(A3) mutant inhibited FOXM1 and VEGF expression, at
protein and mRNA levels, respectively (Fig. 3C). Conversely, transiently transfection of
MCF-7 cells with a FOXO3a targeting siRNA pool or non-targeting control siRNA
increased VEGF and FOXM1 expression (Fig. 3D). To demonstrate further that FOXO3a
has a role in the down-regulation of FOXM1 and VEGF by lapatinib treatment, we
transfected the BT474 breast carcinoma cells with either a FOXO3a-specific or a
nonspecific control siRNA pool and studied the expression of VEGF and FOXM1 after
lapatinib treatment (Fig. 3E). Western blot analysis showed that the FOXO3a-specific
siRNA, but not control siRNA, effectively knocked down the expression of endogenous
FOXO3a in the BT474 cells. As observed previously, Lapatinib treatment led to a decrease
in P-HER2 in both control and FOXO3a siRNA cells. However, silencing of FOXO3a
elevated the basal expression levels of FOXM1 and VEGF, and alleviated the down-
regulation of FOXM1 and VEGF by lapatinib. Notably, the expression levels of FOXM1
and VEGF did eventually decline at 48 h after lapatinib, which could be due to the
functional compensation by other FOXO isoforms or the fact that FOXM1 and/or VEGF are
also repressed by lapatinib through other transcription factors or at the post-transcriptional
level. Together these data further confirmed that FOXO3a negatively regulates VEGF and
FOXM1 expression, through a mechanism likely to involve transcriptional inhibition.
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FOXO3a and FOXM1 modulate VEGF promoter activity
We postulated that FOXO3a could suppress VEGF transcription, either by modulating
promoter activity or, indirectly, by inhibiting FOXM1 expression. To differentiate between
these scenarios, a 1741 bp region of the putative VEGF promoter, representing positions
−1,926 to −186 relative to the predominant 5′-transcription start site, was cloned upstream
of a luciferase reporter (Fig. 4A). Co-transfection studies showed that expression of the
FOXO3a(A3) mutant represses the activity from the putative VEGF promoter whereas
exogenous expression of FOXM1 transactivated the reporter construct in a dose-dependent
manner (Fig. 4B). Sequence analysis identified 2 consensus forkhead transcription response
elements (FHREs) in the proximal promoter region. Mutation of the distal (−319) but not the
proximal (−178) FHRE abrogated the ability of FOXO3a(A3) and FOXM1 to inhibit and
activate, respectively, this promoter-reporter construct. Thus, a single response element,
designated FHRE2, appears to mediate the effects of both transcription factors on the VEGF
promoter.
FOXO3a and FOXM1 compete for binding to FHRE2
To provide more insight into the mechanism by which FOXO3a and FOXM1 regulates the
VEGF promoter, we performed oligonucleotide pull-down assay with nuclear lysates from
unstimulated MDA-MB-231-FOXO3a(A3):ER and MDA-MB-231 cells or cells treated with
4-OHT for 8 and 24 h. Western blot analysis of the pulled-down complexes showed that
both FOXO3a and FOXM1 bind to the wild-type FHRE2 of VEGF, but not the mutated
FHRE2 site (Fig. 4C). The binding of FOXO3a and FOXM1 to the FHRE2 could be
competed off by excess amounts of the wild-type but not mutated FHRE2 oligonucleotides,
indicating that both transcription factors bind directly to this response element (Fig. 4C).
The results also revealed that FOXM1 is constitutively bound to FHRE2 in untreated MDA-
MB-231-FOXO3a(A3):ER and the MDA-MB-231 cells. However, FOXM1 was replaced by
the FOXO3a(A3):ER in response to 4-OHT stimulation of MDA-MB-231-FOXO3a(A3):ER
but not of MDA-MB-231 cells, suggesting that activated FOXO3a down-regulates VEGF
expression by competitive displacing FOXM1 bound to FHRE2.
The FHRE pull-down experiment was then repeated in the BT474 cells following lapatinib
treatment in the presence of molar excess of mutated FHRE oligonucleotides (Fig. 4C).
Parallel Western blot analysis of nuclear and cytoplasmic lysates showed that lapatinib
induces nuclear accumulation of FOXO3a after 2 to 4 hours, concomitant with the down-
regulation of VEGF expression but without discernible change in FOXM1 levels at these
time-points (Fig. 4D). The pull-down results, however, indicated that the lapatinib-activated
FOXO3a displaces FOXM1 from the FHRE2 of the VEGF promoter at these time-points.
Thus, although prolonged activation of FOXO3a will down-regulate FOXM1 levels,
inhibition of VEGF expression is an early event and mediated, at least in part, by displacing
FOXM1 and binding to FHRE2. Consistent with this, we have also obtained data from
FHRE pull-down and chromatin immunoprecipitation (ChIP) assays, suggesting that
FOXO3a can displace FOXM1 binding to the FHRE2 of the VEGF promoter (Fig. S9).
Conversely, FOXM1 was unable to compete FOXO3a off the VEGF promoter. The finding
that FOXO3a can displace FOXM1 from the VEGF FHRE2 and not vice versa is further
supported by a recent structural study of the FOXM1 DNA-recognition domain
demonstrating that FOXM1 has a lower DNA-binding affinity to the consensus ‘TAAACA’
recognition sequence compared with other forkhead proteins (Littler et al 2010).
FOXO3a is recruited to the proximal region of the VEGF promoter in vivo
We next performed chromatin ChIP assays to determine the in vivo occupancy of the VEGF
promoter in the BT474 cells in response to lapatinib treatment. The anti-FOXO3a antibody,
but not the control antibody (IgG), precipitated the proximal region, encompassing FHRE2,
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of the VEGF promoter in BT474 cells (Fig 4E). The amount of precipitated DNA increased
significantly following 2 h of lapatinib treatment, reflecting enhanced occupancy of
FOXO3a to this region of the VEGF promoter in vivo, consistent with the DNA pull-down
results. In contrast, the binding of FOXM1 decreased at 2 h following lapatinib treatment.
Notably, the binding of both the FOXO3a and FOXM1 to the VEGF promoter decreased
substantially by 4 h, probably suggesting decreased accessibility to the proximal region of
the VEGF promoter. This observation pointed to the possibility that FOXO3a play a role in
recruiting chromatin remodelling enzymes, such as histone deacetylases (HDACs), to
repress the VEGF transcription.
FOXO3a recruits HDAC2 to the VEGF promoter
To test the hypothesis that FOXO3a recruits HDACs to repress VEGF transcription, we first
treated MCF-7 cells with the HDAC inhibitor TSA and monitored VEGF expression. RT-
qPCR and Western blot analyses demonstrated that TSA strongly enhances VEGF mRNA
and protein levels (Fig. 5A). TSA also triggered a marked induction in VEGF promoter
activity, which was abolished upon mutation of the FHRE2, but not FHRE1, site.
Conversely, overexpression of the dominantly active HDAC2C262A/C274A mutant, but not
the wild-type HDAC2, repressed VEGF promoter activity in a dose-dependent manner (Fig.
5B). This ability of HDAC2 to repress VEGF promoter activity was again dependent on a
functional FHRE2. The inability of wild-type HDAC2 to repress VEGF promoter activity
could be due to the high levels of endogenous HDAC2 in MCF-7 cells. ChIP assays further
demonstrated that TSA induced a decrease in HDAC2 binding to the proximal VEGF
promoter (Fig. 5C). Finally, HDAC2 knockdown using siRNA significantly up-regulated
VEGF expression whereas silencing of HDAC1 silencing had little or no effect on VEGF
expression. Combined, the data provide compelling evidence that HDAC2 mediates
transcriptional inhibition of the VEGF promoter in breast cancer cells.
To examine if FOXO3a recruits HDAC2 to the VEGF promoter, we performed
immunoprecipitation and ChIP experiments on BT474 cells treated with lapatinib. HDAC2
and FOXO3a co-immunoprecipitated and this interaction was enhanced upon lapatinib
treatment, probably reflecting nuclear translocation of FOXO3a (Fig. 6A). ChIP assays
showed increased recruitment of HDAC2 to the proximal VEGF promoter after 2 h of
lapatinib treatment (Fig. 6B). Histone H3 and H4 acetylation are epigenetic marks
associated with activated promoters (Bernstein et al 2005, Davie and Candido 1978).
HDAC2 recruitment coincided with a decrease in bound acetylated histones H3 and H4,
indicating active chromatin remodelling and compaction of the proximal VEGF promoter.
Further, siRNA-mediated FOXO3a knockdown (Fig. 6C and 6D) in BT474 cells abolished
the recruitment of HDAC2 to the proximal VEGF promoter upon lapatinib treatment as well
as the concomitant decrease in acetylated histones H3 and H4. These findings demonstrate
that FOXO3a activation in breast cancer cells results in displacement of DNA-bound
FOXM1, binding to FHRE2, recruitment of HDAC2, and transcriptional repression of
VEGF.
Discussion
Signals mediated through VEGFs and their receptors have been shown to be essential for
breast cancer carcinogenesis, cell migration (metastasis) and angiogenesis (Lohela et al
2009). Yet, the molecular mechanisms regulating VEGF expression in cancer cells are only
partially understood. A previous cDNA microarray study using a colon carcinoma cell line
DLD-1 has suggested that FOXO3a can potentially repress VEGF expression (Delpuech et
al 2007). Our present analysis of breast cancer patient samples revealed that FOXO3a
nuclear localisation is significantly but inversely associated with VEGF expression,
suggesting FOXO3a negatively regulates VEGF expression in vivo in breast cancer.
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Using the lapatinib sensitive breast cancer cell lines BT474 and SKBR3 as models for
FOXO3a activation, the hypothesis that FOXO3a regulates VEGF expression was examined
and the underlying mechanisms involved explored in the present study. lapatinib treatment
resulted in inactivation of the phosphatidylinositol-3-kinase (PI-3K) pathway, nuclear
translocation and activation of FOXO3a (Hegde et al 2007) and ultimately reduction in
VEGF expression at protein, mRNA and gene promoter levels. Transient transfection and
inducible FOXO3a expression experiments showed that FOXO3a represses while FOXM1
activates VEGF expression through a proximal FHRE site of the VEGF promoter, as
mutation of this FHRE abrogated the regulation by FOXO3a and FOXM1. ChIP and
oligonucleotide pull-down assays further demonstrated that both FOXO3a and FOXM1 bind
directly to the FHRE of the VEGF promoter and that activated FOXO3a can displace
FOXM1 from the FHRE, suggesting that FOXO3a can repress VEGF expression through
competing off the transcriptional activator FOXM1. Consistently, FOXO3a accumulated and
replaced FOXM1 at the FHRE as early as 2 h after lapatinib treatment; however, it was also
noted that neither FOXO3a nor FOXM1 bound to the FHRE by 4 h. The lack of occupancy
of the proximal VEGF promoter region by FOXO3a and FOXM1 at 4 h suggested that
FOXO3a accumulation might lead to exclusion of transcription factors through chromatin
remodelling. Histone acetylation decondenses the chromatin, making nucleosomal DNA
more accessible to transcription factors, whereas inhibition of histone deacetylase activity by
HDACs leads to condensation of the chromatin and exclusion of transcription factors.
Consistently, we found that upon activation, FOXO3a recruits HDAC2 to the proximal
region of the VEGF promoter, as revealed by ChIP analysis. Current evidence also proposes
that transcriptionally active DNA is located in nucleosomes with acetylated histones H3 and
H4. Our ChIP assays showed that in response to lapatinib treatment in BT474 cells, there
was an increase in FOXO3a and HDAC2 binding, concomitant with a decrease in acetylated
histones H3 and H4 levels. We performed co-immunoprecipitation experiments to examine
the amount of HDAC2 binding to FOXO3a in response to lapatinib in BT474 cells. The
results showed that the amount of HDAC2 interacting with FOXO3a increased substantially
at 2 h but declined by 4 h following lapatinib treatment. The increase in FOXO3a binding to
HDAC2 in response to lapatinib is likely to be due to the relocation of FOXO3a to the
nucleus, while the declined in FOXO3a binding to HDAC2 was probably a result of the
disassociation in binding between the two proteins as well as a decline in HDAC2 levels, as
revealed by immunoprecipitaion and western blot analyses, respectively.
Overexpression of FOXM1 has been implicated with metastasis and angiogenesis in a
number of malignancies, including glioma, gastric and pancreatic cancer. Consistent with
our findings, a recent study has also demonstrated that FOXM1 transcriptionally regulates
VEGF expression in glioma cells (Zhang et al 2008). It is notable that the FOXM1
responsive sites identified previously locate over 500 bp 5′-upstream of the FOXO/FOXM1
binding site defined in this study and neither of these sites appears to be a consensus FOXO-
binding element. Importantly, deletion of site 2 in the present VEGF promoter abolishes
responsiveness to FOXO3a, FOXM1 and HDAC, suggesting this FHRE is targeted by
FOXO3a and FOXM1. In the present study we further demonstrated that FOXM1 functions
downstream of FOXO3a, and its activity and expression are negatively regulated by
FOXO3a. Nevertheless, FOXM1 is not the sole effector of FOXO3a function. FOXO3a can
also negatively regulate gene expression through FOXM1 independent mechanisms, such as
by means of HDAC recruitment. The ability of FOXO proteins to repress VEGF expression
has been documented in Foxo1 null cells where VEGF is overexpressed and angiogenesis
deregulated (Furuyama et al 2004, Park et al 2009). This notion is now supported further by
our finding that expression of nuclear FOXO3a expression significantly inversely correlates
with VEGF expression in breast cancer patient samples. Consistently, constitutively active
FOXO mutants have been shown to inhibit HUVEC cell migration, and capillary tube
formation (Davis et al 2009, Lee et al 2008).
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In summary, together the present results suggest that FOXO3a can potentially repress VEGF
expression, through at least two mechanisms. First, activated FOXO3a can compete off the
transcription activator FOXM1 from binding to the FHRE of the VEGF gene promoter.
Second, FOXO3a can recruit HDACs to the VEGF promoter to induce chromatin
condensation and transcription factor exclusion. Furthermore, FOXO3a has also been shown
previously to be able to repress FOXM1 expression at transcriptional levels (Francis et al
2009). Consequently, FOXO3a can repress VEGF expression indirectly via regulating
FOXM1 expression. The mechanisms by which FOXO3a represses VEGF expression may
represent common means whereby FOXO3a negatively regulates target gene expression.
Thus, the present study also provides novel understanding on the mechanisms by which
FOXO transcription factors repress target gene expression. Furthermore, the findings from
this study also suggest that therapeutic strategies targeting FOXO3a or FOXM1 can be used
as an alternative or in parallel with anti-VEGF targeted agents as well as conventional
chemotherapy in rational and effective treatment of tumours (Fernandez de Mattos et al
2008, Gomes et al 2008, Srivastava et al 2010).
Materials and Methods
Cell Culture
The human breast carcinoma cell lines BT474, SKBR3, MCF-7, and MDA-MB-231
originated from the American Type Culture Collection and were acquired from the Cell
Culture Service, Cancer Research UK (London, UK), where they were tested and
authenticated. Cell lines used in the present study were in culture for less than 6 months. All
cells used were maintained in Dulbecco’s modified Eagle’s medium supplemented with 10%
fetal bovine serum, 2 mM glutamine, and 100 units/ml penicillin/streptomycin at 37 °C.
Lapatinib was obtained from GlaxoSmithKline, dissolved in DMSO and used at a final
concentration of 0.1 μM.
Plasmids
For the generation of human VEGF promoter constructs, a 1741 bp VEGF promoter
construct was generated using PCR primers 5′-
ATCTCGAGGAGGCTATGCCAGCTGTAGG-3′ and 5′-
GCAAGCTTTCTGCTGGTTTCCAAAATCC-3′ from genomic DNA and cloned into the
pGL3 basic vector (Promega, Southampton, United Kingdom). Putative forkhead site
mutagenesis was performed using a Stratagene QuikChange site-directed mutagenesis kit.
The HDAC2WT and HDAC2C262A/C274A expression plasmids were kind gifts from Dr.
Antonella Riccio (University College London, UK) (Nott et al 2008) and the FOXO3a(A3)
or FOXM1(ΔN) expression vectors have previously been described (Essafi et al 2005, Krol
et al 2007, Kwok et al 2008).
Luciferase reporter assay, Antibodies, Real-time quantitative PCR (RT-qPCR) and Gene
Silencing with Small Interfering RNAs (siRNAs)
See Supplementary Materials and Methods.
Western Blotting
Western blotting was performed on whole cell extracts as described previously (Krol et al
2007).
Preparation of nuclear and cytoplasmic extracts
Nuclear and cytoplasmic extracts were prepared as previously described (Essafi et al 2009).
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Pull-down assays using biotin-labelled oligonucleotides
Pull-down assays were performed as described previously (Labied et al 2006) using the
100nmol of biotin-labelled double stranded oligonucleotides: Wild-type (5′-
GTTTTATCCCTCTTCTTTTTTCTTAAACATTTTTTAAA-3′) Mutant: (5′-
GTTTTATCCCTGTTCTTTTTTCTTGGGCATTTTTTAAA-3′). The pulled down
complexes were then analysed by Western blotting.
Tissue Microarray and Immnohistochemistry
See Fig. 1 legend
Chromatin Immunoprecipitation (ChIP) assay—ChIP assay was performed as
described (Essafi et al 2005) using FOXO3a(A3):ER MDA-MB-231 cells treated with or
without 200nM 4-OHT for 24 hours before harvesting. DNA fragments were purified using
the QIAquick Spin Kit (Qiagen, UK). For PCR, one-twenty-fifth of the extracted DNA was
used and amplified in 25 PCR cycles using specific primers. PCRs were then performed on
the purified DNA using the following primers: (−351)-5′-
TCCGGGTTTTATCCCTCTTC-3′; 5′-TCTGCTGGTTTCCAAAATCC-3′ (−186).
Statistical analysis
To test for the relationship between VEGF, FOXM1 and nuclear/cytoplasmic FOXO3a,
statistical analysis was performed using Pearson’s correlation test and was considered
significant at p≤0.05 and very significant at ≤0.01 All statistical analysis was performed
with SPSS v.16 (SPSS inc, Chicago, IL, USA).
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Figure 1. Representative expression patterns of FOXO3a, FOXM1 and VEGF in tissue
microarray
One hundred and thirty-three cases of breast cancer diagnosed between the years 1992 to
2001 with clinical follow up data available were retrieved from the records of the
Department of Pathology, Queen Mary Hospital of Hong Kong. The patients’ ages at
diagnosis ranged from 30 to 90 years old, with a mean of 53 years. Histological sections of
all cases were reviewed by the pathologist, the representative paraffin tumour blocks chosen
as donor block for each case and the selected areas marked for construction of tissue
microarray blocks. Tissue sections were deparaffinised, rehydrated and stained with a
previously described primary polyclonal FOXO3a specific antibody (Nordigarden et al
2009, Rosivatz et al 2006) (diluted at 1:1400), the VEGF antibody (dilution 1:250) and
FOXM1 (C-20, dilution 1:450, Santa Cruz). A total of 116 could be assessed and scored for
FOXO3a, FOXM1 and VEGF expression using a scanscope (Scanscope Aperio
Technologies, Inc, Vista, Calif) connected to a personal computer as described in figure S1.
The expression pattern and subcellular localization were correlated with histological type,
histological grade, clinical stage, estrogen and progestrogen receptor status, HER2
oncoprotein overexpression, lymph node metastasis and survival time (Fig. S2 and S3).
Tumour tissue samples obtained from breast cancer patients that had been formalin-fixed
and paraffin-embedded were immunohistochemically stained with FOXO3a, FOXM1 and
VEGF antibodies using the streptavidin-biotin-peroxidase technique. Scoring was performed
as described in Fig. S1. A) Three representative tumour cases showing corresponding
FOXO3a FOXM1 and VEGF staining patterns (magnification: x 100; insets x400). The
three cases 1, 2 and 3 represent low, medium and high FOXO3a cytoplasmic staining. Cases
1 and 2 also show nuclear FOXO3a staining and low FOXM1 and VEGF staining, while
case 3 shows predominantly strong cytoplasmic FOXO3a staining, and strong FOXO3a and
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VEGF staining. B) Correlation analysis of FOXO3a, FOXM1 and VEGF staining in 116
breast carcinoma cases. The correlation between predominant nuclear/cytoplasmic FOXO3a
expression with FOXM1 and VEGF expression and FOXM1 with VEGF expression was
studied using Chi-Square Tests and was considered significant * at p≤0.05 and very
significant ** at p≤0.01.
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Figure 2. Expression of FOXO3a, FOXM1 and VEGF in response to lapatinib treatment in
breast cancer cell lines
The lapatinib sensitive BT474 and SKBR-3 and resistant MDA-MB-231 cells were cultured
in 10% FCS medium for 24 h before treatment with lapatinib. A) At times indicated, cells
were collected and analysed for P-FOXO3a, total FOXO3a, FOXM1, VEGF, FGF7,
LaminB and tubulin expression by western blotting of nuclear/cytoplamic (left panel) and
total (right panel) lysates. B) VEGF concentrations in supernatants of the lapatinib-treated
breast cancer cells were measured by a quantitative sandwich enzyme immunoassay
according to the manufacturer’s protocol (Quantikine ELISA, R&D Systems, Abingdon,
UK). The optical density was measured at 450nm using a Sunrise-Tecan plate reader
(TECAN Ltd, Reading, UK) and VEGF concentrations normalised using standard curves. C)
In parallel, VEGF mRNA levels of these lapatinib-treated breast cancer cells were also
analysed by qRT-PCR and normalized to L19 RNA expression. Total RNA (2 μg) isolated
using the RNeasy Mini kit (Qiagen, Crawley, UK) was reverse transcribed using the
Superscript III reverse transcriptase and random primers (Invitrogen, Paisley, UK), and the
resulting first strand cDNA was used as template in the real-time PCR. All experiments were
performed in triplicate. The following gene-specific primer pairs were designed using the
ABI Primer Express software: FOXM1-sense: 5′-TGCAGCTAGGGATGTGAATCTTC-3′
and FOXM1-antisense: 5′-GGAGCCCAGTCCATCAGAACT-3′; ERα-sense: 5′-
CAGATGGTCAGTGCCTTGTTGG-3′ and ERα-antisense: 5′-
CCAAGAGCAAGTTAGGAGCAAACAG-3′; L19-sense 5′-
GCGGAAGGGTACAGCCAAT-3′ and L19-antisense 5′-GCAGCCGGCGCAAA-3′.
Specificity of each primer was determined using NCBI BLAST module. Real time PCR was
performed with ABI PRISM 7700 Sequence Detection System using SYBR Green
Mastermix (Applied Biosystems, Brackley, UK). The RT-qPCR results shown are
representative of 3 independent experiments.
FOXM1 mRNA levels of these cells were also analysed by RT-qPCR, and normalized with
L19 RNA expression.
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Figure 3. FOXO3a represses the expression of FOXM1 and VEGF in the breast carcinoma cells
MDA-MB-231 and MCF-7
A) MDA-MB-231-FOXO3a(A3):ER and MDA-MB-231 cells were treated with 200 nmol/L
4-OHT for the indicated times. Nuclear and cytoplasmic extracts were prepared at the times
indicated, separated on polyacrylamide gels, and subjected to immunoblotting with specific
antibodies. The expression levels of FOXO3a(A3):ER, FOXO3a, P-FOXO3a, FOXM1,
VEGF, FGF7, tubulin and Lamin B1 were analyzed by Western blotting and the VEGF
concentrations in supernatants of the 4-OHT-treated MDA-MB-231 cells cells were
measured by the quantitative sandwich enzyme immunoassay as described in Fig. 2B. B)
Total RNA was extracted from these cells and analyzed for FOXM1 and VEGF mRNA
expression using RT-qPCR as described in the text and normalized to the level of L19 RNA.
C) MCF-7 cells transiently transfected with the constitutively active FOXO3a(A3) or
control vector were analysed for VEGF and FOXM1 expression by western blot and RT-
qPCR analysis. D) MCF-7 cells transiently transfected with FOXO3a or control siRNA, or
mock transfected were analysed by western blot using specific antibodies FOXO3a,
FOXM1, VEGF and tubulin as indicated and by RT-qPCR for VEGF and FOXM1 mRNA
expression. All data shown represent the averages of data from three experiments, and the
error bars show the standard deviations. E) BT474 cells transiently transfected with control
or FOXO3a siRNA, were treated with lapatinib for 0, 16, 24 and 48 h. Protein lysates were
prepared at the times indicated and analyzed by western blot using specific antibodies P-
HER2, HER-2, P-FOXO3a, FOXO3a, FOXM1, VEGF and tubulin as indicated.
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Figure 4. FOXO3a represses and FOXM1 induces the transcriptional activity of the human
VEGF gene through a FHRE consensus site proximal to the transcription start site
A) Effect of expression of FOXO3a and FOXM1 on VEGF promoter activity. Schematic
representation of the VEGF-luciferase reporter construct, showing the consensus FHRE
sequences. A 1741 bp VEGF promoter construct (positions −1,926 to −186 relative to the
predominant 5′-transcription start site) was cloned into the XhoI and HindIII sites of the
pGL3 basic vector (Promega, Southampton, United Kingdom). Putative forkhead site
mutagenesis was performed using a Stratagene QuikChange site-directed mutagenesis kit
with the oligonucleotides: Site1 (−178) (5′-
ATCCCTCTTCTTTTTTCTTGGGCATTTTTTTTTAAAACTGTATTGT-3′), and Site2
(−319) (5′- TTGCTCTACTTCCCCGGGTCACTGTGGATTTTGGGGGCCAGCAGA-3′).
B) MCF-7 cells were transiently transfected with 20 ng of either the wild-type, (VEGF pro-
WT), mutant FHRE1 (VEGF pro-mut1), or mutant FHRE2 (VEGF pro-mut2) VEGF
promoter/reporter and 0, 5, 10 or 20 ng of either the constitutively active FOXO3a(A3) or
FOXM1(ΔN) expression vector. Cells were harvested 24 h after transfection and assayed for
luciferase activity. All relative luciferase activity values are corrected for cotransfected
Renilla activity. All data shown represent the averages of data from three independent
experiments, and the error bars show the standard deviations. C) MDA-MB-231-
FOXO3a(A3):ER and MDA-MB-231 cells were treated with 200 nmol/L 4-OHT for the
indicated times. Nuclear extracts prepared were incubated with biotinylated wild-type or
mutant FHRE2 oligonucleotides in the presence or absence of 5x molar excess of non-
biotinylated wild-type or mutant FHRE2 oligonucleotides. Proteins binding to the
biotinylated oligonucleotides were pulled-down using streptavidine agarose beads and
analysed by western blot using specific antibodies as indicated. D) The nuclear and
cytoplasmic extracts prepared from BT474 cells treated with lapatinib for 0, 2 and 4 h were
western blotted for proteins indicated (right panel). The nuclear extracts from the lapatinib-
treated cells were also examined by pull-down assays using biotinylated wild-type or mutant
FHRE2 oligonucleotides as described above. E) Chromatin immunoprecipitation (ChIP)
analysis of the human VEGF promoter. MDA-MB-231-FOXO3a(A3):ER, MDA-MB-231
and BT474 cells described above were used for ChIP assays using IgG, anti-FOXO3a and
anti-FOXM1 antibodies as indicated. After crosslink reversal, the co-immunoprecipitated
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DNA was amplified by PCR using primers amplifying the VEGF FHRE2 containing region
(−351/−186) and resolved in 2% agarose gel. Representative data from three independent
experiments are shown.
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Figure 5. Effects of HDAC2 overexpression and depletion on the expression of VEGF in MCF-7
cells
A) MCF-7 cells treated with vehicle or 100 nM trichostatin A (TSA; Sigma, UK) for 24 h
were harvested for RT-qPCR and western blot analysis for VEGF expression. B) MCF-7
cells transiently transfected with 20 ng of either the wild-type, (VEGF pro-WT), mutant
FHRE1 (VEGF pro-mut1), or mutant FHRE2 (VEGF pro-mut2) VEGF promoter/reporter
were either untreated or treated with 100 nM TSA, or co-tranfected with 0, 5, 10 or 20 ng of
either the wild-type or constitutively active HDAC2 expression vector. The transfected cells
were then harvested for luciferase assays after 24 h. C) MCF-7 cells untreated or treated
with TSA for 24 h were analysed for HDAC2 binding on the VEGF promoter by ChIP
assays as described. D) MCF-7 cells were transiently transfected with control and smart pool
siRNA against either HDAC1 or HDAC2 and analysed by western blotting for protein
expression as indicated.
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Figure 6. OXO3a recruits HDAC2 to the VEGF promoter in response to lapatinib in BT474 cells
A) Cell extracts prepared from BT474 cells 0, 2 and 4 h after treatment with lapatinib were
immunoprecipitated (IP) with antibodies against FOXO3a and HDAC2 or an IgG control
antibody. The precipitated complexes and the inputs were examined for FOXO3a and
HDAC2 expression. B) BT474 cells were transiently transfected with smart pool siRNA
against FOXO3a or control siRNA pool. Twenty-four h afterwards, the transfected BT474
cells were treated with lapatinib for 0, 2, or 4 h and then analysed for HDAC2, acetylated
histone H3 and H4 binding on the VEGF promoter by ChIP assays as described. C) Western
blot and RT-qPCR analyses were performed as described to demonstrate effective and
specific FOXO3a knock-down.
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